# Stem Cell Therapy for Inflammatory Diseases: Progress, Challenges, and Future Directions

## TL;DR

This review explores how stem cell therapies can treat inflammatory diseases like arthritis and bowel disease, highlighting promising strategies and challenges.

## Contribution

The paper provides a comparative analysis of clinical stem cell strategies and proposes solutions to translational barriers in inflammatory disease treatment.

## Key findings

- Targeted delivery systems show superior efficacy in managing localized inflammatory lesions and tissue restoration.
- Minimally processed interventions like autologous fat grafting demonstrate unexpected therapeutic promise.
- iPSC platforms and precision genetic modifications are proposed as strategic solutions for improving stem cell therapies.

## Abstract

Inflammatory diseases, encompassing conditions like inflammatory bowel disease and rheumatoid arthritis, present a significant clinical challenge with substantial treatment‐refractory patient populations despite biologic therapy advances. Stem cell therapeutics have emerged as a transformative approach, leveraging multifaceted regenerative mechanisms to address the complex pathophysiology of these conditions, which involves genetic, microbial, immunological, and epithelial dysregulation. This review focuses on comparing the clinical efficacy of contemporary stem cell strategies. We analyze outcomes across diverse cell sources, with a detailed examination of delivery methodologies. Our systematic analysis demonstrates superior efficacy with targeted delivery systems, particularly in managing localized inflammatory lesions (e.g., fistulas) and tissue restoration. Notably, minimally processed cellular interventions, such as autologous fat grafting and stromal vascular fraction therapy, show unexpected therapeutic promise. Critical translational barriers include suboptimal cell homing, limited engraftment persistence, and uncharacterized long‐term safety profiles. We propose strategic solutions through induced pluripotent stem cell platforms, precision genetic modifications, and advanced delivery technologies. By integrating mechanistic insights with robust clinical evidence, this review establishes an evidence‐based framework for optimizing stem cell therapeutics in inflammatory disease management. The analysis addresses fundamental scalability and safety considerations while identifying promising avenues for personalized regenerative medicine approaches in treatment‐refractory inflammatory conditions.

Stem cells offer multifaceted therapeutic approaches for inflammatory diseases, each exhibiting distinct therapeutic properties. Hematopoietic stem cells, primarily through hematopoietic stem cell transplantation (HSCT), can effectively remodel the immune environment, showing particular promise in treating genetically linked cases. Mesenchymal stem cells (MSCs) demonstrate broad therapeutic potential through immunomodulation, tissue regeneration, intestinal microbiota regulation, and fistula repair. Tissue‐specific stem cells (TSCs) and induced pluripotent stem cells (iPSCs) currently serve primarily as research tools for understanding disease mechanisms and as platforms for drug screening. Furthermore, the potential of intestinal transplantation using TSC‐derived organoids represents a promising future therapeutic direction.